BMO Capital analyst, Gary Nachtman, reiterated his Outperform rating on shares of Neos Therapeutics (NASDAQ: NEOS) after meeting with management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE